C. Tissa Kappagoda – författare
Visar alla böcker från författaren C. Tissa Kappagoda. Handla med fri frakt och snabb leverans.
4 produkter
4 produkter
Inbunden, Engelska, 1996
893 kr
Skickas inom 10-15 vardagar
Inbunden, Engelska, 1987
1 115 kr
Skickas inom 10-15 vardagar
The management of patients who present with a myocardial i nfarcti on has altered radi ca lly over the past two decades. The expansion of knowledge relating to the epidemiology of the condition together with a greater understanding of the causes of the early mortality from it have resulted in major changes in the way these pati ents are treated duri ng the acute phase of the illness. The deve 1 opment of 'dedi cated' Coronary Care Units in hospitals and the recogni ti on of the need for ' Mobile Coronary Care Units' in the cOl1Ul1unity have made a major impact upon the early mortality from myocardial infarction. Over the past decade, a great deal of attention has been paid to strategies designed to limit the size of a myocardial infarct. As an extensi on of thi s approach, the 1980' s have seen the evo 1 uti on of techniques for revascularization of ischemic tissue. All these procedures while appearing to hold the promise of reducing the acute mortality from myocardial infarction, create the need for a planned approach to the long term management of these patients.While there are some modest i ndi cati ons that coronary atherosc 1 erosi s coul d be arrested or even reversed, for all practical purposes it remains a chroni c progressi ve di sease.
Del 84 - Developments in Cardiovascular Medicine
Long-Term Management of Patients After Myocardial Infarction
Häftad, Engelska, 2011
1 115 kr
Skickas inom 10-15 vardagar
The management of patients who present with a myocardial i nfarcti on has altered radi ca lly over the past two decades. The expansion of knowledge relating to the epidemiology of the condition together with a greater understanding of the causes of the early mortality from it have resulted in major changes in the way these pati ents are treated duri ng the acute phase of the illness. The deve 1 opment of 'dedi cated' Coronary Care Units in hospitals and the recogni ti on of the need for ' Mobile Coronary Care Units' in the cOl1Ul1unity have made a major impact upon the early mortality from myocardial infarction. Over the past decade, a great deal of attention has been paid to strategies designed to limit the size of a myocardial infarct. As an extensi on of thi s approach, the 1980' s have seen the evo 1 uti on of techniques for revascularization of ischemic tissue. All these procedures while appearing to hold the promise of reducing the acute mortality from myocardial infarction, create the need for a planned approach to the long term management of these patients.While there are some modest i ndi cati ons that coronary atherosc 1 erosi s coul d be arrested or even reversed, for all practical purposes it remains a chroni c progressi ve di sease.
Häftad, Engelska, 2012
561 kr
Skickas inom 10-15 vardagar
On April 8-9, 1994, a symposium entitled Control of the Cardiovascular and Respiratory Systems in Health and Disease was held at the University of California Davis Medical Center in Sacramento. The purpose of this symposium was to honor the careers of Professors Hazel M. and John C. G. Coleridge. Participants in this symposium came from throughout the world. Their attendance at the symposium was a symbol of great respect and affection for the honorees. The Professors Coleridge have made many important contribu tions to the scientific literature concerning neural control of the cardiovascular and respira tory systems. In addition, they have made remarkable contributions to the lives of other scientists working in this field of investigation. Some of us have known them as mentors, counselors, friends, and supervisors; others have known them as co-investigators. Most importantly, all of us have known them as friends. This book, which contains the proceedings of the symposium, is dedicated to Hazel and John Coleridge. C. T. Kappagoda M. P. Kaufman v ACKNOWLEDGMENTS We wish to acknowledge the financial support of the following agencies for making this symposium a reality: • Astra Merck Group (Tarek Ackad, M. D. , Ph. D. ) • Boehringer Ingelheim Pharmaceuticals, Inc. (Ms. Kathryn B. Lucas and Mr. Allan Holloway) • Bristol-Myers Squibb (David L. Cram, Jr. , Pharm. D. ) • Marion/Merrrell Dow, Inc. (Mr. Brian Scheffield) • Merck and Company (Mr. Johnathan Sakakibara) • Pfizer Laboratories (Mr.